IN2014DN00200A - - Google Patents
Info
- Publication number
- IN2014DN00200A IN2014DN00200A IN200DEN2014A IN2014DN00200A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A IN 200DEN2014 A IN200DEN2014 A IN 200DEN2014A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A
- Authority
- IN
- India
- Prior art keywords
- riluzole
- subject
- methods
- reducing
- auc24h
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 7
- 229960004181 riluzole Drugs 0.000 abstract 7
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN00200A true IN2014DN00200A (enExample) | 2015-06-05 |
Family
ID=47506929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN200DEN2014 IN2014DN00200A (enExample) | 2011-07-13 | 2012-07-12 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (enExample) |
| EP (1) | EP2731611B1 (enExample) |
| JP (2) | JP6145946B2 (enExample) |
| KR (1) | KR101951220B1 (enExample) |
| CN (2) | CN109316480A (enExample) |
| AU (2) | AU2012281042B2 (enExample) |
| BR (1) | BR112014000742A2 (enExample) |
| CA (1) | CA2849213A1 (enExample) |
| EA (2) | EA201791043A1 (enExample) |
| HK (1) | HK1197178A1 (enExample) |
| IL (1) | IL230391B (enExample) |
| IN (1) | IN2014DN00200A (enExample) |
| PH (1) | PH12014500094A1 (enExample) |
| SG (1) | SG10201605707UA (enExample) |
| WO (1) | WO2013010015A2 (enExample) |
| ZA (1) | ZA201400236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| LT3137622T (lt) | 2014-04-29 | 2022-04-25 | Cytokinetics, Inc. | Gyvybinio pajėgumo nykimo mažinimo būdai |
| RS59490B1 (sr) * | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| CA2967659A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EA038531B1 (ru) | 2016-03-25 | 2021-09-10 | Аб Сьянс | Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб |
| EP4031135A4 (en) | 2019-09-20 | 2023-10-18 | Icahn School of Medicine at Mount Sinai | CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| KR100756592B1 (ko) | 1999-10-08 | 2007-09-10 | 그뤼넨탈 게엠베하 | 비사이클릭 이미다조-3-일-아민 유도체, 이의 제조방법 및 이를 포함하는 진통제 |
| HUP0203140A3 (en) | 1999-10-08 | 2004-06-28 | Gruenenthal Gmbh | Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| US20030083318A1 (en) | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| US7476665B2 (en) | 2003-06-26 | 2009-01-13 | Merck & Co., Inc. | Benzodiazepine CGRP receptor antagonists |
| EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| EP1694323A4 (en) | 2003-12-19 | 2009-05-13 | Elixir Pharmaceuticals Inc | METHOD FOR TREATING A DISEASE |
| EP1715855A4 (en) | 2004-01-29 | 2010-06-16 | Elixir Pharmaceuticals Inc | ANTIVIRAL DRUGS |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AU2005289644A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| CN101189238A (zh) | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2008016648A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| BRPI0714725B1 (pt) * | 2006-08-02 | 2021-05-25 | Cytokinetics, Inc | Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química |
| CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| ES2547303T3 (es) | 2007-01-19 | 2015-10-05 | Ardea Biosciences, Inc. | Inhibidores de MEK |
| US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP2018854A1 (en) | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2713864A1 (en) | 2008-02-04 | 2009-08-13 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| CA2730473A1 (en) | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| AU2010262970A1 (en) | 2009-06-19 | 2012-01-12 | Knopp Neurosciences, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2013151938A1 (en) | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
| BR112014025251B1 (pt) | 2012-04-11 | 2021-03-02 | Fady Malik | uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo |
| LT3137622T (lt) | 2014-04-29 | 2022-04-25 | Cytokinetics, Inc. | Gyvybinio pajėgumo nykimo mažinimo būdai |
-
2012
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104039148A (zh) | 2014-09-10 |
| PH12014500094A1 (en) | 2014-03-17 |
| ZA201400236B (en) | 2014-10-29 |
| US10272082B2 (en) | 2019-04-30 |
| WO2013010015A2 (en) | 2013-01-17 |
| KR101951220B1 (ko) | 2019-02-22 |
| IL230391B (en) | 2019-03-31 |
| HK1197178A1 (en) | 2015-01-09 |
| KR20140074270A (ko) | 2014-06-17 |
| JP6145946B2 (ja) | 2017-06-14 |
| AU2012281042A1 (en) | 2014-01-30 |
| US20140243344A1 (en) | 2014-08-28 |
| EP2731611B1 (en) | 2019-09-18 |
| NZ619924A (en) | 2016-02-26 |
| SG10201605707UA (en) | 2016-09-29 |
| BR112014000742A2 (pt) | 2016-08-23 |
| CN109316480A (zh) | 2019-02-12 |
| JP2014520856A (ja) | 2014-08-25 |
| EA201791043A1 (ru) | 2017-09-29 |
| EP2731611A4 (en) | 2015-02-18 |
| AU2012281042B2 (en) | 2016-07-14 |
| EA028060B1 (ru) | 2017-10-31 |
| AU2016244263A1 (en) | 2016-11-03 |
| WO2013010015A3 (en) | 2014-05-15 |
| EA201490011A1 (ru) | 2014-08-29 |
| EP2731611A2 (en) | 2014-05-21 |
| CA2849213A1 (en) | 2013-01-17 |
| JP2017128610A (ja) | 2017-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500094A1 (en) | Combination als therapy | |
| GB201016812D0 (en) | Method and apparatus for treating respiratory diesease | |
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| MX2014004548A (es) | Metodos para tratar pacientes pediatricos usando dexmedetomidina. | |
| EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
| IN2015DN00376A (enExample) | ||
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| MX2013008715A (es) | Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2014013503A (es) | Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno. | |
| CA2866819C (en) | Method for treating inflammation | |
| NZ597115A (en) | Method of treating age related disorders with fujimycin | |
| MX2010013790A (es) | Composiciones y metodos para tratar inflamacion de corneas. | |
| WO2008129239A3 (en) | Use of agents that inhibit homologous recombination for the treatment of cancer | |
| WO2011156715A3 (en) | Methods of treating metabolic disorders and cardiovascular diseases | |
| MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| IN2014DN05769A (enExample) | ||
| MX2021000380A (es) | Tecnicas de inyeccion para el tratamiento de la celulitis. | |
| MX364643B (es) | USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. | |
| UA62637U (ru) | Способ лечения вегетативных и тревожных расстройств у больных с синдромом вегетативной дистонии | |
| UA70889U (ru) | Способ лечения диабетической ретинопатии | |
| EA201992284A1 (ru) | Композиции и способы лечения синуклеинопатий |